Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.55 |
| ▸ | LTA4H | P09960 | 9/20 | 0.54 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TACR2 | P21452 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4881619 | 1.00 | FPR2 (0.55) | FPR2LTA4HNOX1NPC1RAB9A | |
| SCHEMBL4600092 | 0.90 | LTA4H (0.67) | FPR2LTA4HNOX1NPC1RAB9A | |
| SCHEMBL4599431 | 0.90 | LTA4H (0.67) | FPR2LTA4HNOX1NPC1RAB9A | |
| SCHEMBL4598883 | 0.90 | LTA4H (0.67) | FPR2LTA4HNOX1NPC1RAB9A | |
| SCHEMBL4598882 | 0.89 | LTA4H (0.66) | FPR2LTA4HNOX1NPC1RAB9A | |
| SCHEMBL4598874 | 0.89 | LTA4H (0.66) | FPR2LTA4HNOX1NPC1RAB9A | |
| SCHEMBL4600154 | 0.89 | LTA4H (0.62) | FPR2LTA4HNOX1NPC1RAB9A | |
| SCHEMBL4599698 | 0.89 | LTA4H (0.62) | FPR2LTA4HNOX1NPC1RAB9A | |
| SCHEMBL4599694 | 0.89 | LTA4H (0.62) | FPR2LTA4HNOX1NPC1RAB9A | |
| SCHEMBL4599643 | 0.85 | LTA4H (0.58) | FPR2LTA4HCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | FPR2 3112/4885LTA4H 2507/4885NOX1 2601/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | FPR2 3738/4885LTA4H 1884/4885NOX1 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.